Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Announces Rs. 317 crore investment in new recycling plant
Overall investment in the US facility is estimated around US$50 million
Melicica has potential applications in skin repair, scar and acne-prone skin care, tone evening and brightening, texture improvement, baby care, sensitive skin solutions, post-procedure recovery and stretch mark care
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
Subscribe To Our Newsletter & Stay Updated